Work

Elevated Bromide Levels Due to Tazemetostat Therapy Treated With Salt and Water Supplementation in Two Children With Atypical Teratoid Rhabdoid Tumor

Year: 2025

Type: article

Abstract: Atypical teratoid rhabdoid tumor (ATRT) is an embryonal CNS tumor that afflicts young children. The molecular process associated with ATRT is loss of SMARCB1 or SMARCA4, which causes EZH2 overactivation. Tazemetostat hydrobromide is an EZH2 inhibitor, which has shown efficacy in the treatment of ATRT. Tazemetostat is produced as a bromide salt and can cause increased bromide levels that may require therapy cessation or dose reduction. We report two children with ATRT, who developed elevated bromide levels secondary to tazemetostat, which were treated with chloride. We propose consideration of salt supplementation in children receiving tazemetostat to prevent bromide elevation and pauses or reductions in therapy.

Source: Pediatric Blood & Cancer

DOI: 10.1002/pbc.31803

Authors: Thomas J. Galletta, Stefanie W. Benoit, Justin Markham, Natasha Pillay‐Smiley, Kate Queen, Richard T. Graham

Institutions: Cincinnati Children's Hospital Medical Center, University of Cincinnati

Language: English

Topic: Chromatin Remodeling and Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,640